Granted Patent
B2
US 12,473,547 · App. 16/766,206 · Granted Nov 18, 2025
Use of mesenchymal lineage precursor cells or stem cells (MLPSCs) for delivery of oligonucleotides in the treatment of cancer
Inventors:
Peter Brink (New York, NY); Ira Cohen (New York, NY); Richard Lin (New York, NY); Sergey Doronin (New York, NY); Irina Potapova (New York, NY); Virginijus Valiunas (New York, NY); Dan Devine (New York, NY); Anthony Sandrasagra (New York, NY); Nick Loizos (New York, NY); Silviu Itescu (Melbourne, AU)
Assignee:
Mesoblast International Sàrl
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present disclosure relates to cellular compositions that are modified to introduce a nucleic acid or vector expressing the same. Such compositions may be used to deliver nucleic acid to a target cell and treat disease such as cancer.
Claims (10)
1 . A method of treating a cancer in a subject, the method comprising administering to the subject a composition comprising mesenchymal precursor cells (MPCs) or mesenchymal stem cells (MSCs), wherein said MPCs or MSCs comprise an siRNA to KRAS G12D and contact target cancer cells in the subject, whereby the MPCs or MSCs form gap junctions with the contacted target cancer cells, and wherein said cancer comprises an oncogenic G12D mutation in KRAS.
2 . The method of claim 1 , wherein the composition comprises MPCs.
3 . The method of claim 2 , wherein the MPCs express tissue non-specific alkaline phosphatase (TNAP).
4 . The method of claim 1 , wherein the cancer is prostate cancer.
5 . The method of claim 1 , wherein the cancer is a pancreatic cancer or a colorectal cancer.
6 . The method of claim 1 , wherein the MPCs or MSCs are culture- expanded.
7 . The method of claim 1 , wherein the MPCs or MSCs are derived from pluripotent cells.
8 . The method of claim 1 , wherein the target cancer cells are non- syncytial cancer cells.
9 . The method of claim 1 , wherein the target cancer cells are syncytial cells.
10 . The method of claim 1 , wherein the MPCs or MSCs express a viral vector.
Assignments (3)
RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY
Recorded Jan 2, 2026
From: OAKTREE FUND ADMINISTRATION, LLC, AS AGENT
To: MESOBLAST LIMITED; MESOBLAST UK LIMITED; MESOBLAST, INC. (FORMERLY KNOWN AS ANGIOBLAST, INC.); MESOBLAST INTERNATIONAL SÀRL
Reel/Frame 074174/0183 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Apr 12, 2023
From: BRINK, PETER; COHEN, IRA; LIN, RICHARD; DORONIN, SERGEY; POTAPOVA, IRINA; VALIUNAS, VIRGINIJUS; DEVINE, DAN; SANDRASAGRA, ANTHONY; LOIZOS, NICK; ITESCU, SILVIU
To: MESOBLAST INTERNATIONAL SARL
Reel/Frame 063311/0001 →
SECURITY INTEREST
Recorded Dec 10, 2021
From: MESOBLAST LIMITED ACN 109 431 870; MESOBLAST UK LIMITED; MESOBLAST, INC. (FORMERLY KNOWN AS ANGIOBLAST, INC.); MESOBLAST INTERNATIONAL SÀRL
To: OAKTREE FUND ADMINISTRATION, LLC
Reel/Frame 058957/0447 →
Continuity (2)
Provisional Application
62589764
· Nov 22, 2017
References Cited (356)
US 5197985A
· Caplan, I et al.
· 1993
[cited by applicant]
US 5226914A
· Caplan et al.
· 1993
[cited by applicant]
US 5486359A
· Caplan et al.
· 1996
[cited by applicant]
US 5578475A
· Jessee
· 1996
[cited by applicant]
US 5591625A
· Gerson et al.
· 1997
[cited by applicant]
US 5643736A
· Bruder et al.
· 1997
[cited by applicant]
US 5736396A
· Bruder et al.
· 1998
[cited by applicant]
US 5827740A
· Pittenger
· 1998
[cited by applicant]
US 5855619A
· Caplan et al.
· 1999
[cited by applicant]
US 5908784A
· Johnstone et al.
· 1999
[cited by applicant]
US 5965436A
· Thiede et al.
· 1999
[cited by applicant]
US 6020202A
· Jessee
· 2000
[cited by applicant]
US 6022540A
· Bruder et al.
· 2000
[cited by applicant]
US 6030836A
· Thiede et al.
· 2000
[cited by applicant]
US 6051429A
· Hawley-Nelson et al.
· 2000
[cited by applicant]
US 6149906A
· Mosca
· 2000
[cited by applicant]
US 6261549B1
· Fernandez et al.
· 2001
[cited by applicant]
US 6328960B1
· McIntosh et al.
· 2001
[cited by applicant]
US 6355239B1
· Bruder et al.
· 2002
[cited by applicant]
US 6368636B1
· McIntosh et al.
· 2002
[cited by applicant]
US 6387367B1
· Davis-Sproul et al.
· 2002
[cited by applicant]
US 6387369B1
· Pittenger et al.
· 2002
[cited by applicant]
US 6482231B1
· Abatangelo et al.
· 2002
[cited by applicant]
US 6541024B1
· Kadiyala et al.
· 2003
[cited by applicant]
US 6627442B1
· Humeau et al.
· 2003
[cited by applicant]
US 6653134B2
· Prockop et al.
· 2003
[cited by applicant]
US 6685936B2
· McIntosh et al.
· 2004
[cited by applicant]
US 6723561B2
· Russell et al.
· 2004
[cited by applicant]
US 6761887B1
· Kavalkovich et al.
· 2004
[cited by applicant]
US 6797269B2
· Mosca et al.
· 2004
[cited by applicant]
US 6835377B2
· Goldberg et al.
· 2004
[cited by applicant]
US 6875430B2
· McIntosh et al.
· 2005
[cited by applicant]
US 6905678B2
· Havenga et al.
· 2005
[cited by applicant]
US 6936281B2
· Seshi
· 2005
[cited by applicant]
US 6974571B2
· Prockop et al.
· 2005
[cited by applicant]
US 7078230B2
· Wilkison et al.
· 2006
[cited by applicant]
US 7153500B2
· Qasba et al.
· 2006
[cited by applicant]
US 7344711B2
· Bonastre et al.
· 2008
[cited by applicant]
US 7364900B2
· Black et al.
· 2008
[cited by applicant]
US 7491388B1
· McIntosh et al.
· 2009
[cited by applicant]
US 7615374B2
· Vodyanyk et al.
· 2009
[cited by applicant]
US 7732203B2
· Suh et al.
· 2010
[cited by applicant]
US 8105580B2
· Fraser et al.
· 2012
[cited by applicant]
US 8142773B2
· Aslan et al.
· 2012
[cited by applicant]
US 8147824B2
· Maziarz et al.
· 2012
[cited by applicant]
US 8404229B2
· Fraser et al.
· 2013
[cited by applicant]
US 8440177B2
· Gonzalez et al.
· 2013
[cited by applicant]
US 8486695B2
· Danilkovitch et al.
· 2013
[cited by applicant]
US 8637004B2
· Danilkovich et al.
· 2014
[cited by applicant]
US 8940293B2
· Li et al.
· 2015
[cited by applicant]
US 8962318B2
· Lim et al.
· 2015
[cited by applicant]
US 9050178B2
· Barry et al.
· 2015
[cited by applicant]
US 9095562B2
· Centeno et al.
· 2015
[cited by applicant]
US 9453203B2
· May et al.
· 2016
[cited by applicant]
US 9694035B2
· Aggarwal et al.
· 2017
[cited by applicant]
US 9814580B2
· Barry et al.
· 2017
[cited by applicant]
US 9828586B2
· Tom et al.
· 2017
[cited by applicant]
US 9943547B2
· Aggarwal et al.
· 2018
[cited by applicant]
US 9963678B2
· Tom et al.
· 2018
[cited by applicant]
US 20020037278A1
· Ueno et al.
· 2002
[cited by applicant]
US 20020064519A1
· Bruder et al.
· 2002
[cited by applicant]
US 20030059412A1
· Prockop et al.
· 2003
[cited by applicant]
US 20030118567A1
· Stewart
· 2003
[cited by applicant]
US 20030165482A1
· Rolland et al.
· 2003
[cited by applicant]
US 20040018174A1
· Palasis
· 2004
[cited by applicant]
US 20040033214A1
· Young et al.
· 2004
[cited by applicant]
US 20040166097A1
· Prockop et al.
· 2004
[cited by applicant]
US 20040241145A1
· Hata et al.
· 2004
[cited by applicant]
US 20050008626A1
· Fraser et al.
· 2005
[cited by applicant]
US 20050031600A1
· Mickle et al.
· 2005
[cited by applicant]
US 20050048035A1
· Fraser et al.
· 2005
[cited by applicant]
US 20050048036A1
· Hedrick et al.
· 2005
[cited by applicant]
US 20050095228A1
· Fraser et al.
· 2005
[cited by applicant]
US 20050153442A1
· Katz et al.
· 2005
[cited by applicant]
US 20050158397A1
· Chopp et al.
· 2005
[cited by applicant]
US 20050239897A1
· Pittenger et al.
· 2005
[cited by applicant]
US 20050260174A1
· Fraser et al.
· 2005
[cited by applicant]
US 20050260175A1
· Hedrick et al.
· 2005
[cited by applicant]
US 20060063141A1
· McGann et al.
· 2006
[cited by applicant]
US 20060083720A1
· Fraser et al.
· 2006
[cited by applicant]
US 20060134596A1
· Sjogren et al.
· 2006
[cited by applicant]
US 20060275272A1
· Li et al.
· 2006
[cited by applicant]
US 20060280729A1
· Mistry
· 2006
[cited by applicant]
US 20070036768A1
· Fraser et al.
· 2007
[cited by applicant]
US 20070123996A1
· Sugaya et al.
· 2007
[cited by applicant]
US 20070253931A1
· Varney et al.
· 2007
[cited by applicant]
US 20080095749A1
· Aggarwal et al.
· 2008
[cited by applicant]
US 20080175825A1
· Hampson et al.
· 2008
[cited by applicant]
US 20080213227A1
· Aggarwal et al.
· 2008
[cited by applicant]
US 20080219957A1
· Lim et al.
· 2008
[cited by applicant]
US 20080241113A1
· Walton et al.
· 2008
[cited by applicant]
US 20080292592A1
· Chada et al.
· 2008
[cited by applicant]
US 20090010896A1
· Centeno et al.
· 2009
[cited by applicant]
US 20090180997A1
· Pittenger et al.
· 2009
[cited by applicant]
US 20090208463A1
· Pittenger et al.
· 2009
[cited by applicant]
US 20090214487A1
· Varney et al.
· 2009
[cited by applicant]
US 20090220464A1
· Aggarwal et al.
· 2009
[cited by applicant]
US 20090324609A1
· Lodie et al.
· 2009
[cited by applicant]
US 20100034793A1
· McNiece et al.
· 2010
[cited by applicant]
US 20100040583A1
· Falanga
· 2010
[cited by applicant]
US 20100166712A1
· Sadiq et al.
· 2010
[cited by applicant]
US 20100172885A1
· Pittenger et al.
· 2010
[cited by applicant]
US 20100330048A1
· Aggarwal et al.
· 2010
[cited by applicant]
US 20110027238A1
· Aggarwal et al.
· 2011
[cited by applicant]
US 20110142807A1
· Pittenger et al.
· 2011
[cited by applicant]
US 20110195054A1
· Cohen et al.
· 2011
[cited by applicant]
US 20110200612A1
· Schuster et al.
· 2011
[cited by applicant]
US 20110311496A1
· Pittenger et al.
· 2011
[cited by applicant]
US 20110318314A1
· Aggarwal et al.
· 2011
[cited by applicant]
US 20110318315A1
· Aggarwal et al.
· 2011
[cited by applicant]
US 20120052049A1
· Woods et al.
· 2012
[cited by applicant]
US 20120201791A1
· Yoo
· 2012
[cited by applicant]
US 20120269774A1
· Ichim et al.
· 2012
[cited by applicant]
US 20130330300A1
· Shi et al.
· 2013
[cited by applicant]
US 20140027321A1
· Langh-Lagerlof
· 2014
[cited by applicant]
US 20140105872A1
· Danilkovich et al.
· 2014
[cited by applicant]
US 20140273211A1
· Slukvin et al.
· 2014
[cited by applicant]
US 20140328807A1
· Aggarwal et al.
· 2014
[cited by applicant]
US 20140363522A1
· Lengyel
· 2014
[cited by examiner]
US 20150272997A1
· Aggarwal et al.
· 2015
[cited by applicant]
US 20150307844A1
· Sturm
· 2015
[cited by applicant]
US 20160199413A1
· Simonson et al.
· 2016
[cited by applicant]
US 20160361362A1
· Koblar et al.
· 2016
[cited by applicant]
US 20170107495A1
· Itescu et al.
· 2017
[cited by applicant]
US 20180008642A1
· Danilkovich et al.
· 2018
[cited by applicant]
US 20180021380A1
· Han et al.
· 2018
[cited by applicant]
US 20180087032A1
· Danilkovich et al.
· 2018
[cited by applicant]
US 20190240259A1
· Aggarwal et al.
· 2019
[cited by applicant]
US 20200197444A1
· Danilkovich et al.
· 2020
[cited by applicant]
US 20200231936A1
· Tom et al.
· 2020
[cited by applicant]
US 20200246387A1
· Aggarwal et al.
· 2020
[cited by applicant]
US 20200345781A1
· Honmou et al.
· 2020
[cited by applicant]
US 20210171913A1
· Danilkovitch et al.
· 2021
[cited by applicant]
US 20220079991A1
· Itescu
· 2022
[cited by applicant]
US 20220143097A1
· Itescu et al.
· 2022
[cited by applicant]
US 20220160776A1
· Itescu et al.
· 2022
[cited by applicant]
US 20220226386A1
· Itescu
· 2022
[cited by applicant]
US 20220275337A1
· Devine et al.
· 2022
[cited by applicant]
US 20220364059A1
· Bukulmez et al.
· 2022
[cited by applicant]
US 20230076630A1
· Aggarwal et al.
· 2023
[cited by applicant]
US 20230089901A1
· Danilkovich et al.
· 2023
[cited by applicant]
US 20230097931A1
· Itescu
· 2023
[cited by applicant]
US 20230104108A1
· Itescu
· 2023
[cited by applicant]
US 20230165904A1
· Itescu
· 2023
[cited by applicant]
US 20230172991A1
· Itescu
· 2023
[cited by applicant]
US 20230220349A1
· Simmons
· 2023
[cited by applicant]
US 20230293589A1
· Itescu
· 2023
[cited by applicant]
US 20230293590A1
· Itescu et al.
· 2023
[cited by applicant]
US 20230398154A1
· Itescu et al.
· 2023
[cited by applicant]
US 20240041934A1
· Istescu et al.
· 2024
[cited by applicant]
US 20240091266A1
· Itescu et al.
· 2024
[cited by applicant]
US 20240197787A1
· Itescu
· 2024
[cited by applicant]
US 20240207323A1
· Itescu et al.
· 2024
[cited by applicant]
CA 2473108A1
· 2003
[cited by applicant]
CA 2736353A1
· 2010
[cited by applicant]
CN 1382450A
· 2002
[cited by applicant]
CN 1536075A
· 2004
[cited by applicant]
CN 108715833A
· 2018
[cited by applicant]
CN 111297899A
· 2020
[cited by applicant]
CN 112522191A
· 2021
[cited by applicant]
EP 1279738A1
· 2003
[cited by applicant]
EP 2476751A1
· 2012
[cited by applicant]
EP 3583945A1
· 2019
[cited by applicant]
ES 2385450T3
· 2012
[cited by applicant]
KR 20200015174A
· 2020
[cited by applicant]
WO WO9630031A1
· 1996
[cited by applicant]
WO WO9741208A1
· 1997
[cited by applicant]
WO WO9951247A1
· 1999
[cited by applicant]
WO WO0049136A1
· 2000
[cited by applicant]
WO WO0126470A1
· 2001
[cited by applicant]
WO WO2001080865A2
· 2001
[cited by applicant]
WO WO03080083A1
· 2003
[cited by applicant]
WO WO03082200A2
· 2003
[cited by applicant]
WO WO2004003164A2
· 2004
[cited by applicant]
WO WO2004052177A2
· 2004
[cited by applicant]
WO WO2004085630A1
· 2004
[cited by applicant]
WO WO2005059111A2
· 2005
[cited by applicant]
WO WO2004022579A3
· 2005
[cited by applicant]
WO WO2005086922A2
· 2005
[cited by applicant]
WO WO2005093044A1
· 2005
[cited by applicant]
WO WO2006108229A1
· 2006
[cited by applicant]
WO WO2006112365A1
· 2006
[cited by applicant]
WO WO2006136244A2
· 2006
[cited by applicant]
WO WO2007087139A2
· 2007
[cited by applicant]
WO WO2007088229A1
· 2007
[cited by applicant]
WO WO2007124594A1
· 2007
[cited by applicant]
WO WO2007127408A2
· 2007
[cited by applicant]
WO WO2008011133A2
· 2008
[cited by applicant]
WO WO2008110579A2
· 2008
[cited by applicant]
WO WO2008116157A2
· 2008
[cited by applicant]
WO WO2008141177A1
· 2008
[cited by applicant]
WO WO2009028870A2
· 2009
[cited by applicant]
WO WO2010019886A1
· 2010
[cited by applicant]
WO WO2010108931A1
· 2010
[cited by applicant]
WO WO2010111522A2
· 2010
[cited by examiner]
WO WO2010128182A1
· 2010
[cited by applicant]
WO WO2012048093A2
· 2012
[cited by applicant]
WO WO2013005053A2
· 2013
[cited by applicant]
WO WO2013112942A1
· 2013
[cited by applicant]
WO WO2013116778A2
· 2013
[cited by applicant]
WO WO2014204814A1
· 2014
[cited by applicant]
WO WO2015016761A2
· 2015
[cited by applicant]
WO WO2015077624A1
· 2015
[cited by applicant]
WO WO2015089280A1
· 2015
[cited by applicant]
WO WO2015166082A1
· 2015
[cited by applicant]
WO WO2016086020A1
· 2016
[cited by applicant]
WO WO2016102601A1
· 2016
[cited by applicant]
WO WO2016139340A1
· 2016
[cited by applicant]
WO WO2017132358A1
· 2017
[cited by applicant]
WO WO2017144552A1
· 2017
[cited by applicant]
WO WO2017165641A1
· 2017
[cited by applicant]
WO WO2018002930A1
· 2018
[cited by applicant]
WO WO2018023114A1
· 2018
[cited by applicant]
WO WO2018053529A1
· 2018
[cited by applicant]
WO WO2018182612A1
· 2018
[cited by applicant]
WO WO2018202853A1
· 2018
[cited by applicant]
WO WO2019051623A1
· 2019
[cited by applicant]
WO WO2019102268A1
· 2019
[cited by applicant]
WO WO2020141473A1
· 2020
[cited by applicant]
WO WO2020141483A1
· 2020
[cited by applicant]
WO WO2020157660A1
· 2020
[cited by applicant]
WO WO2020234450A1
· 2020
[cited by applicant]
WO WO2021024207A1
· 2021
[cited by applicant]
WO WO2021165420A1
· 2021
[cited by applicant]
WO WO2021176001A1
· 2021
[cited by applicant]
WO WO2021180850A1
· 2021
[cited by applicant]
WO WO2021180851A1
· 2021
[cited by applicant]
WO WO2021198454A1
· 2021
[cited by applicant]
WO WO2022034506A1
· 2022
[cited by applicant]
WO WO2022132986A2
· 2022
[cited by applicant]
WO WO2022159731A1
· 2022
[cited by applicant]
WO WO2024121820A1
· 2024
[cited by applicant]
Torres et al, PLOS One, vol. 8. Issue 11, e80580 (12 pages total) (Year: 2013).
[cited by examiner]
Gradiz et al, Scientific Reports, vol. 6:21648 (14 pages) (Year: 2016).
[cited by examiner]
Akimov, S.S., et al., “Bypass of senescence, immortalization, and transformation of human hematopoietic progenitor cells,” Stem Cells, 23(9):1423-1433, AlphaMed Press, North Carolina (2005).
[cited by applicant]
Bader, A.G., et al., “Developing therapeutic microRNAs for cancer,”
[cited by applicant]
Barberi, et al., “Derivation of Multipotent Mesenchymal Precursor from Human Embryonic Stem Cells,”
[cited by applicant]
Brink, P.R., et al., “Can gap junctions deliver?”
[cited by applicant]
Brink, P.R., et al., “In vivo cellular delivery of siRNA,”
[cited by applicant]
Griffiths-Jones, S., “The microRNA Registry,”
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/IB2008/001439, European Patent Office, Netherlands, mailed on May 6, 2019, 20 pages.
[cited by applicant]
Kabara, M., et al., “Immortalized multipotent pericytes derived from the vasa vasorum in the injured vasculature. A cellular tool for studies of vascular remodeling and regeneration,”
[cited by applicant]
Kozomara, A., et al., “miRBase: annotating high confidence microRNAs using deep sequencing data,”
[cited by applicant]
Lennox, K.A., and Behlke, M.A., “Chemical Modification and Design of Anti-miRNA Oligonucleotides,”
[cited by applicant]
Liu, S., et al., “Connexin43 Mediated Delivery of ADAMTS5 Targeting siRNAs from Mesenchymal Stem Cells to Synovial Fibroblasts,”
[cited by applicant]
Matuskova, M., et al., “Intrinsic properties of tumour cells have a key impact on the bystander effect mediated by genetically engineered mesenchymal stromal cells,”
[cited by applicant]
NCBI Reference Sequence NM_004523.3,
[cited by applicant]
Obinata, M., “Conditionally immortalized cell lines with differentiated functions established from temperature-sensitive T-antigen transgenic mice.”
[cited by applicant]
Pereboeva, L., et al., “Approaches to utilize mesenchymal progenitor cells as cellular vehicles,”
[cited by applicant]
Rimkute, L., et al., “The role of neural connexins in HeLa cell mobility and intercellular communication through tunneling tubes,”
[cited by applicant]
Simmons, P.J. and Torok-Storb, B., “Identification of stromal cell precursors in human bone marrow by a novel monoclonal antibody, STRO-1,”
[cited by applicant]
Vodyanik, M.A., et al., “A mesoderm-derived precursor for mesenchymal stem and endothelial cells,”
[cited by applicant]
Co-pending Application, U.S. Appl. No. 16/815,784, inventors Aggarwal, S., et al., filed on Mar. 11, 2020, (Not Published).
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/IB2021/057381, mailed Nov. 12, 2021, 12 pages.
[cited by applicant]
International Search Report and Written Opinion for Application No. PCT/IB2020/057410, mailed Oct. 6, 2020, 11 pages.
[cited by applicant]
Fleming, J. B., et al., “Molecular consequences of silencing mutant K-ras in pancreatic cancer cells: justification for K-ras-directed therapy,” Mol Cancer Res 3(7):413-423, American Association for Cancer Research, Uni…
[cited by applicant]
Lv, F.J., et al., “Concise Review: the Surface Markers and Identity of Human Mesenchymal Stem Cells,” Stem Cells 32(6):1408-1419, AlphaMed Press, United States (Jun. 2014).
[cited by applicant]
Co-pending Application, U.S. Appl. No. 17/906,160, inventor Itescu, S., filed Sep. 12, 2022 (US 20230172991).
[cited by applicant]
Co-pending Application, U.S. Appl. No. 17/906,150, inventor Itescu, S., filed Sep. 12, 2022 (US 20230104108).
[cited by applicant]
Co-pending Application, U.S. Appl. No. 17/905,742, inventor Itescu, S., filed Sep. 6, 2022 (Not Yet Published).
[cited by applicant]
Co-pending Application, U.S. Appl. No. 17/995,385, inventor Itescu, S., filed Oct. 3, 2022 (US 20230165904).
[cited by applicant]
Aggarwal, S., et al., “Human Mesenchymal Stem Cells Modulate Allogeneic Immune Cell Responses,” Blood 105(4):1815-1822, American Society of Hematology, United States (Feb. 2005).
[cited by applicant]
Al-Khaldi, A., et al., “Postnatal Bone Marrow Stromal Cells Elicit A Potent VEGF-dependent Neoangiogenic Response In Vivo,” Gene Therapy 10(8):621-629, Nature Publishing Group, United Kingdom (Apr. 2003).
[cited by applicant]
Al-Khaldi, A.A., et al., “Therapeutic Angiogenesis Using Autologous Bone Marrow Stromal Cells: Improved Blood Flow In a Chronic Limb Ischemia Model,” Annals of Thoracic Surgery 75(1):204-209, Elsevier, Netherlands (Jan.…
[cited by applicant]
Al-Khaldi, A.A., et al., “VEGF-Dependent Angiogenic Response Induced by Ex-Vivo Cultured Marrow Stromal Cells,” Circulation 104(17):123, Lippincott Williams & Wilkins, United States (2001).
[cited by applicant]
Baksh, D., et al., “Adult Mesenchymal Stem Cells: Characterization, Differentiation, and Application in Cell and Gene Therapy,” Journal of Cellular and Molecular Medicine 8(3):301-316, Wiley-Blackwell, United Kingdom (J…
[cited by applicant]
Ballas, C.B., et al., “Adult Bone Marrow Stem Cells For Cell and Gene Therapies: Implications For Greater Use,” Journal of Cellular Biochemistry 38:20-28, Wiley, United States (2002).
[cited by applicant]
Barry, F.P and Murphy, J.M., “Mesenchymal Stem Cells: Clinical Applications and Biological Characterization,” International Journal of Biochemistry & Cell Biology 36:568-584, Elsevier, Netherlands (Apr. 2004).
[cited by applicant]
Barry, F.P., “Biology And Clinical Applications of Mesenchymal Stem Cells,” Birth Defects Research Part C: Embryo Today 69(3):250-256, Wiley, United States (Aug. 2003).
[cited by applicant]
Bobis, S., et al., “Mesenchymal Stem Cells: Characteristics and Clinical Applications,” Folia Histochemica ET Cytobiologica 44(4):215-230, Polish Histochemical and Cytochemical Society at VM Media, Poland (2006).
[cited by applicant]
Chulpanova, D.S., et al., “Application of Mesenchymal Stem Cells for Therapeutic Agent Delivery in Anti-tumor Treatment,” Frontiers in Pharmacology 9:259, Frontiers Media, Switzerland (Mar. 2018).
[cited by applicant]
De Miguel, M.P., et al., “Immunosuppressive Properties of Mesenchymal Stem Cells: Advances and Applications,” Current Molecular Medicine 12(5):574-591, Bentham Science Publishers, Netherlands (Jun. 2012).
[cited by applicant]
Deans, R.J. and Moseley, A.B., “Mesenchymal Stem Cells: Biology and Potential Clinical Uses,” Experimental Hematology 28(8):875-884, Elsevier Science Inc., Netherlands (Aug. 2000).
[cited by applicant]
Deng, Y., et al., “Efficiency of Adenoviral Vector Mediated CTLA4Ig Gene Delivery Into Mesenchymal Stem Cells,” Chinese Medical Journal 116(11):1649-1654, Chinese Medical Association, China (Nov. 2003).
[cited by applicant]
Devine, S.M., et al., “Mesenchymal Stem Cells Distribute To a Wide Range of Tissues Following Systemic Infusion into Nonhuman Primates,” Blood 101(8):2999-3001, American Society of Hematology, United States (Apr. 2003).
[cited by applicant]
Djouad, F., et al., “Immunosuppressive Effect of Mesenchymal Stem Cells Favors Tumor Growth in Allogeneic Animals,” Blood 102(10):3837-3844, American Society of Hematology, United States (Nov. 2003).
[cited by applicant]
Du, W., et al., “Stem Cell-released Oncolytic Herpes Simplex Virus Has Therapeutic Efficacy in Brain Metastatic Melanomas,” Proceedings of the National Academy of Sciences 114(30):E6157-E6165, National Acad Sciences (Ju…
[cited by applicant]
Fischer, U, M., et al., “Pulmonary Passage is a Major Obstacle for Intravenous Stem Cell Delivery: the Pulmonary First-pass Effect,” Stem cells and development 18(5):683-92, Mary Ann Liebert, Inc., United States (Jun. 2…
[cited by applicant]
Fu, X., et al., “Expression of a Fusogenic Membrane Glycoprotein by an Oncolytic Herpes Simplex Virus Potentiates the Viral Antitumor Effect,” Molecular Therapy 7(6):748-754, Cell Press, United States (Jun. 2003).
[cited by applicant]
Gao, J., et al., “The Dynamic in Vivo Distribution of Bone Marrow-derived Mesenchymal Stem Cells After Infusion,” Cells. Tissues. Organs 169(1):12-20, Karger, Switzerland (2001).
[cited by applicant]
Griffin, M.D., et al.,. “Anti-donor Immune Responses Elicited by Allogeneic Mesenchymal Stem Cells: What Have We Learned so Far?,” Immunology and Cell Biology 91(1):40-51, Wiley, United States (Jan. 2013).
[cited by applicant]
Gronthos, S., et al., “Molecular and Cellular Characterisation of Highly Purified Stromal Stem Cells Derived From Human Bone Marrow,” Journal of Cell Science 116(Pt 9):1827-1835, Company of Biologists, United Kingdom (M…
[cited by applicant]
Gronthos, S., et al., “Surface Protein Characterization of Human Adipose Tissue-derived Stromal Cells,” Journal of Cellular Physiology 189(1):54-63, Wiley-Liss, United States (Oct. 2001).
[cited by applicant]
Guedan, S., et al., “GALV Expression Enhances the Therapeutic Efficacy of an Oncolytic Adenovirus by Inducing Cell Fusion and Enhancing Virus Distribution,” Gene Therapy 19(11):1048-1057, Nature Publishing Group, United…
[cited by applicant]
Guo, X.R., et al., “PTEN-mRNA Engineered Mesenchymal Stem Cell-mediated Cytotoxic Effects on U251 Glioma Cells,” Oncology Letters 11(4):2733-2740, Spandidos Publications, Greece (Apr. 2016).
[cited by applicant]
Guo, Z., et al., “Biological Features of Mesenchymal Stem Cells From Human Bone Marrow,” Chinese Medical Journal 114(9):950-953, Wolters Kluwer-Medknow, China (Sep. 2001).
[cited by applicant]
Hackney, J.A., et al., “A Molecular Profile of a Hematopoietic Stem Cell Niche,” PNAS, 99(20): 13061-13066, National Academy of Sciences, United States (Oct. 2002).
[cited by applicant]
Hamada, H., et al., “Mesenchymal Stem Cells (MSC) as Therapeutic Cytoreagents for Gene Therapy,” Cancer Science 96(3):149-156, Wiley Publishing, United Kingdom (Mar. 2005).
[cited by applicant]
Hopkins, B.D., et al., “A Secreted PTEN Phosphatase That Enters Cells To Alter Signaling and Survival,” Science 341(6144):399-402, American Association for the Advancement of Science, United States (Jul. 2013).
[cited by applicant]
Horwitz, E.M., et al., “Clarification of the Nomenclature for MSC: The International Society for Cellular Therapy Position Statement,” Cytotherapy 7(5):393-395, Elsevier, United Kingdom (2005).
[cited by applicant]
Izadpanah, R., et al., “Biologic Properties of Mesenchymal Stem Cells Derived From Bone Marrow and Adipose Tissue,” Journal of Cellular Biochemistry 99(5):1285-1297, Wiley-Liss, United States (Dec. 2006).
[cited by applicant]
Jagasia, M.H., et al., “National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-host Disease: I. The 2014 Diagnosis and Staging Working Group Report,” Biology …
[cited by applicant]
Jiang, Y., et al., “Pluripotency of Mesenchymal Stem Cells Derived From Adult Marrow,” Nature, 418(6893):41-49, Nature Publishing Group, United Kingdom (Jul. 2002).
[cited by applicant]
Jorgensen, C., et al., “Engineering Mesenchymal Stem Cells for Immunotherapy,” Gene Therapy 10(10):928-931, Nature Publishing Group, United Kingdom (2003).
[cited by applicant]
Keshavarz, M., et al. , “Oncolytic Newcastle Disease Virus Delivered by Mesenchymal Stem Cells-engineered System Enhances the Therapeutic Effects Altering Tumor Microenvironment,” Virology Journal 17(1):64, BioMed Centr…
[cited by applicant]
Koc, O.N., et al., “Rapid Hematopoietic Recovery After Coinfusion of Autologous-blood Stem Cells and Culture-expanded Marrow Mesenchymal Stem Cells in Advanced Breast Cancer Patients Receiving High-dose Chemotherapy,” J…
[cited by applicant]
Krause, D.S., et al., “Multi-organ, Multi-lineage Engraftment by a Single Bone Marrow-derived Stem Cell,” Cell 105(3):369-377, Cell Press, United States (May 2001).
[cited by applicant]
Le Blanc, K. and Ringden, O., “Immunobiology of Human Mesenchymal Stem Cells and Future Use in Hematopoietic Stem Cell Transplantation,” Biology of Blood and Marrow Transplantation 11(5):321-334, Carden Jennings Publish…
[cited by applicant]
Le Blanc, K., et al., “HLA Expression and Immunologic Properties of Differentiated and Undifferentiated Mesenchymal Stem Cells,” Experimental Hematology 31(10):890-896, Elsevier Science Inc., Netherlands (Oct. 2003).
[cited by applicant]
Le Blanc, K., “Immunomodulatory Effects of Fetal and Adult Mesenchymal Stem Cells,” Cytotherapy 5(6):485-489, Elsevier, United Kingdom (2003).
[cited by applicant]
Lee, S.T., et al., “Treatment of high-risk acute myelogenous leukaemia by myeloblative chemoradiotherapy followed by co-infusion of T cell-depleted haematopoietic stem cells and culture-expanded marrow mesenchymal stem …
[cited by applicant]
Lindner, U., et al., “Mesenchymal Stem or Stromal Cells: Toward a Better Understanding of Their Biology?” Transfusion Medicine and Hemotherapy 37(2):75-83, S. Karger, Switzerland (Apr. 2010).
[cited by applicant]
Lukomska, B., et al., “Challenges and Controversies in Human Mesenchymal Stem Cell Therapy,” Stem Cells International 2019: Article ID (9628536), SAGE—Hindawi Access to Research, United States (Apr. 2019).
[cited by applicant]
Mahasa, K.J., et al., “Mesenchymal Stem Cells Used as Carrier Cells of Oncolytic Adenovirus Results in Enhanced Oncolytic Virotherapy,” Scientific Reports 10:425, Nature Publishing Group, London (Jan. 2020).
[cited by applicant]
McIntosh, K. and Bartholomew, A., “Stromal Cell Modulation of The Immune System,” Graft Review 3(6):324-8, SAGE Publications, United States (2000).
[cited by applicant]
Mesoblast Limited, “Mesoblast Heart Failure Cell Therapy Receives Orphan Drug Designation From FDA For Prevention Of Gastrointestinal Bleeding In Patients With Left Ventricular Assist Devices,” Investorsmedia.mesoblast.…
[cited by applicant]
Nakashima, H. and Chiocca, E.A., “Switching a Replication-defective Adenoviral Vector Into a Replication-competent, Oncolytic Adenovirus,” Journal of Virology 88(1):345-353, American Society for Microbiology, United Sta…
[cited by applicant]
Newman, R.E., et al., “Treatment of Inflammatory Diseases With Mesenchymal Stem Cells,” Inflammation & Allergy Drug Targets 8(2):110-123, Bentham Science Publishers, United Arab Emirates (Jun. 2009).
[cited by applicant]
Ohlsson, L.B., et al., “Mesenchymal Progenitor Cell-mediated Inhibition of Tumor Growth in Vivo and in Vitro in Gelatin Matrix,” Experimental and Molecular Pathology 75(3):248-255, Elsevier, Netherlands (Dec. 2003).
[cited by applicant]
Pittenger, M.F., and Martin, B.J., “Mesenchymal Stem Cells and Their Potential as Cardiac Therapeutics,” Circ. Res. 95: 9-20, American Heart Association, United States (2004).
[cited by applicant]
Pittenger, M.F., et al., “Multilineage Potential of Adult Human Mesenchymal Stem Cells,” Science 284(5411):143-147, American Association for the Advancement of Science, United States (Apr. 1999).
[cited by applicant]
Prockop, D.J., “Marrow Stromal Cells as Stem Cells for Nonhematopoietic Tissues,” Science 276(5309):71-74, American Association for the Advancement of Science, United States (Apr. 1997).
[cited by applicant]
Ramasamy, R., et al., “The Immunosuppressive Effects of Human Bone Marrow-derived Mesenchymal Stem Cells Target T Cell Proliferation but Not Its Effector Function,” Cellular Immunology 251(2):131-136, Elsevier, Netherla…
[cited by applicant]
Rankin, J.A., “Biological Mediators of Acute Inflammation,” AACN Clinical Issues 15(1):3-17, American Association of Critical-Care Nurses, United States (Jan. 2004).
[cited by applicant]
Rasmusson, I., “Immune Modulation by mesenchymal stem cells,” Experimental Cell Research 312:2169-2179, Elsevier, Netherlands (Jul. 2006).
[cited by applicant]
Rayment, E.A., et al., “Concise Review: Mind the Gap: Challenges in Characterizing and Quantifying Cell- and Tissue-based Therapies for Clinical Translation,” Stem Cells (Dayton, Ohio) 28(5):996-1004, Oxford University …
[cited by applicant]
Ruano, D., et al., “First-in-Human, First-in-Child Trial of Autologous MSCs Carrying the Oncolytic Virus Icovir-5 in Patients with Advanced Tumors,” Molecular Theraphy 28(4):1033-1042, Cell Press, United States (Apr. 20…
[cited by applicant]
Russell, L., et al., “PTEN Expression by an Oncolytic Herpesvirus Directs T-cell Mediated Tumor Clearance,” Nature Communications 9(1):5006, Nature Publishing Group, United Kingdom (Nov. 2018).
[cited by applicant]
Shen, Y.H., et al., “Arg-Gly-Asp (RGD)-modified E1a/E1b Double Mutant Adenovirus Enhances Antitumor Activity in Prostate Cancer Cells in Vitro and in Mice,” PLoS One 11(1):e0147173, Public Library of Science, United Sta…
[cited by applicant]
Sonabend, A.M., et al., “Mesenchymal Stem Cells Effectively Deliver an Oncolytic Adenovirus to Intracranial Glioma,” Stem Cells 26(3):831-841, AlphaMed Press, United States (Mar. 2008).
[cited by applicant]
Tolar, J., et al., “Concise Review: Hitting the Right Spot With Mesenchymal Stromal Cells,” Stem Cells 28(8):1446-1555, Oxford University Press, United Kingdom (Aug. 2010).
[cited by applicant]
Tse, W.T., et al., “Suppression of Allogeneic T-cell Proliferation by Human Marrow Stromal Cells: Implications in Transplantation,” Transplantation 75(3):389-397, Lippincott Williams & Wilkins, United States (Feb. 2003).
[cited by applicant]
Tuli, R., et al., “Characterization of multipotential mesenchymal progenitor cells derived from human trabecular bone,” Stem Cells 21(6):681-693, Oxford University Press, United Kingdom (2003).
[cited by applicant]
Ullah, I., et al., “Human mesenchymal stem cells—current trends and future prospective,” Bioscience Reports 35(2):e00191, Springer, United States (Apr. 2015).
[cited by applicant]
Wagers, A.J., et al., “Cell Fate Determination From Stem Cells,” Gene Therapy 9(10):606-612, Nature Publishing Group, United Kingdom (May 2002).
[cited by applicant]
Yang, Z.S., et al., “Cancer Cell-oriented Migration of Mesenchymal Stem Cells Engineered With an Anticancer Gene (PTEN): An Imaging Demonstration,” Oncology Targets and Therapy 7:441-446, Dove Medical Press, New Zealand…
[cited by applicant]
Zhou, S. Z., et al., “Adeno-associated virus 2-mediated high efficiency gene transfer into immature and mature subsets of hematopoietic progenitor cells in human umbilical cord blood,” J Exp Med 179(6):1867-1875, Rockef…
[cited by applicant]
International Search Report and Written Opinion for Application No. PCT/IB2018/001439, mailed on May 6, 2019, 20 pages.
[cited by applicant]
Samineni, S., et al., “Role of CEACAM1, ECM, and mesenchymal stem cells in an orthotopic model of human breast cancer,” Int J Breast Cancer 2011:381080, Hindawi Limited, Egypt (2011).
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/IB2021/055055, European Patent Office, Netherlands, mailed Sep. 17, 2021, 10 pages.
[cited by applicant]
Dos Santos, F., et al., “Toward a clinical-grade expansion of mesenchymal stem cells from human sources: a microcarrier-based culture system under xeno-free conditions,” Tissue Eng Part C Methods 17(12):1201-1210, Mary …
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/IB2023/062429, European Patent Office, Netherlands, mailed Mar. 5, 2024, 12 pages.
[cited by applicant]
Pereira, T., et al., “MSCs conditioned media and umbilical cord blood plasma metabolomics and composition,” PLoS One 9(11):e113769, Public Library of Science, United States (Nov. 2014).
[cited by applicant]
Eisenberg, C.A., et al., “Establishment of the mesodermal cell line QCE-6. A model system for cardiac cell differentiation,” Circ Res 78(2):205-216, Lippincott Williams and Wilkins Ltd., United States (Feb. 1996).
[cited by applicant]
Pilgrim, C.R., et al., “A Review of Fetal Bovine Serum in the Culture of Mesenchymal Stromal Cells and Potential Alternatives for Veterinary Medicine,” Front Vet Sci 9:859025, Frontiers Media SA, Switzerland (May 2022).
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/IB2021/057314, European Patent Office, Netherlands, mailed Oct. 22, 2021, 10 pages.
[cited by applicant]
Martire, A., et al., “Mesenchymal stem cells attenuate inflammatory processes in the heart and lung via inhibition of TNF signaling,” Basic Res Cardiol 111(5):54, D. Steinkopff-Verlag, Germany (Sep. 2016).
[cited by applicant]
Yan, L., et al., “Critical Role of Tumor Necrosis Factor Signaling in Mesenchymal Stem Cell-Based Therapy for Autoimmune and Inflammatory Diseases,” Front Immunol 9:1658, Frontiers Media SA, Switzerland (Jul. 2018).
[cited by applicant]
Burand, A.J., et al., “Function of Cryopreserved Mesenchymal Stromal Cells With and Without Interferon-γ Prelicensing is Context Dependent,” Stem Cells 35(5):1437-1439, Oxford University Press, United States (May 2017).
[cited by applicant]
Co-pending Application, U.S. Appl. No. 18/484,347, inventor Danilkovitch, A., et al., filed Oct. 10, 2023 (Not yet Published).
[cited by applicant]
Co-pending Application, U.S. Appl. No. 18/711,167, inventor Itescu, S., et al., filed Nov. 17, 2022 (Not yet Published).
[cited by applicant]
Cited By (2)